Abstract
At JADPRO Live 2024, J. Kevin Hicks, PharmD, PhD, FCCP, highlighted advances in targeted therapies, liquid biopsies, and genetic profiling to improve outcomes in patients. He discussed the impact of trials such as FLAURA2 and MARIPOSA on refining treatment for EGFR-mutated NSCLC and the use of pharmacogenomics to guide dosing. Dr. Hicks also described the creation of an innovative cloud-based platform at Moffitt Cancer Center designed to organize genetic testing data and streamline clinical decisions.
